The real life data of ranibizumab use among the diabetic macular edema patients in Turkey: Documenting the improvement with clinical optimization during three consecutive years()

PURPOSE: To report the 12 month real life outcomes of ranibizumab treated diabetic macular edema (DME) patients. METHODS: Treatment naïve DME patients treated with ranibizumab were included. Patients were divided into three groups according to their hospital admittance years (2013, 2014, and 2015) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozkaya, Abdullah, Ozveren, Mehmet, Demircan, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137827/
https://www.ncbi.nlm.nih.gov/pubmed/30224879
http://dx.doi.org/10.1016/j.sjopt.2018.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137827/
https://www.ncbi.nlm.nih.gov/pubmed/30224879
http://dx.doi.org/10.1016/j.sjopt.2018.04.005

Ejemplares similares